A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening

International Journal of Pharmaceutics

Volumn 408, Issue 1-2, 2011, Pages 67-75

  Prot, Jean Matthieu ^a   Videau, Orianne ^b   Brochot, Céline ^c   Legallais, Cécile ^a   Bénech, Henri ^b   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b Institut National de la Recherche Agronomique   (France)

^c INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Biochip; CIME cocktail; Drug screening; Human primary hepatocytes; Metabolism; Microfluidic

Indexed keywords

1 HYDROXYMIDAZOLAM; 3 METHOXYMORPHINAN; 4 HYDROXYMIDAZOLAM; 4 HYDROXYTOLBUTAMIDE; 5 HYDROXYOMEPRAZOLE; AMODIAQUINE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEETHYLAMODIAQUINE; DEXTORPHAN; DEXTROMETHORPHAN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; MIDAZOLAM; MIDAZOLAM MALEATE; OMEPRAZOLE; OMEPRAZOLE SULFONE; PARACETAMOL; PARACETAMOL GLUCURONIDE; PARAXANTHINE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOCHIP; BIOTRANSFORMATION; CELL METABOLISM; CELL STRUCTURE; CELL VIABILITY; CRYOPRESERVATION; DRUG ABSORPTION; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; MASS SPECTROMETRY; MICROFLUIDICS; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

EID: 79953243156     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.01.054     Document Type: Article

References (36)

1. Abelo, A., Anderson, T., Antonsson, M., Knuts Naudot, A., Skanberg, I., Weidolf, L., 2000. Stereoselective metabolism of omeprazole by Human cytochrome P450 enzymes. Drug Metab. Dispos. 28, 966-972.
2. Andersson, T., Miners, J., Veronese, M., Birkett, D., 1994. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmac. 37, 597-604.
3. Allen, J.W., Khetani, S.R., Bhatia, S.N., 2005. Zonation and toxicity in a hepatocyte bioreactor. Toxicol. Sci. 84, 110-119.
4. Baillie, T.A., 2006. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-893.
5. Baudoin, R., Griscom, L., Monge, M., Legallais, C., Leclerc, E., 2007. Development of a renal microchip for in vitro distal tubule models. Biotechnol. Prog. 23, 1245-1253.
6. Bhadriraju, K., Chen, C.S., 2002. Engineering cellular microenvironments to improve cell-based drug testing. Drug Discov. Today 7, 612-620. (Pubitemid 34606016)
7. Bhatia, S.N., Yarmush, M.L., Toner, M., 1997. Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts. J. Biomed. Mater. Res. 34, 189-199.
8. Brandon, E.F.A., Raap, C.D., Meijerman, I., Beijnen, J.H., Schellens, J.H.M., 2003. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 189, 233-246.
9. Chao, P., Maguire, T., Novik, E., Cheng, K.C., Yarmush, M.L., 2009. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 78, 625-632.
10. Erve, J.C.L., 2006. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin. Drug Metabol. Toxicol. 2, 923-946.
11. Gebhardt, R., Hengstler, J.G., Muller, D., Glockner, R., Buenning, P., Laube, B., Schmelzer, E., Ullrich, M., Utesch, D., Hewitt, N., Ringel, M., Hilz, B.R., Bader, A., Langsch, A., Koose, T., Burger, H.J., Maas, J., Oesch, F., 2003. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 35, 145-213.
12. Gomez-Lechon, M.J., Castell, J.V., Donato, M.T., 2007. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem. Biol. Interact. 168, 30-50.
13. Guillouzo, A., 1998. Liver cell models in in vitro toxicology. Environ. Health Perspect. 106, 511-532.
14. Guillouzo, A., Morel, F., Langouët, S., Maheo, K., Rissel, M., 1997. Use of hepatocyte cultures for the study of hepatotoxic compounds. J. Hepatol. 26, 73-80.
15. Hewitt, N.J., Hewitt, P., 2004. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34, 243-256. (Pubitemid 38478893)
16. Hewitt, N.J., Lechón, M.J.G., Houston, J.B., Hallifax, D., Brown, H.S., Maurel, P., Kenna, J.G., Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A.P., LeCluyse, E., Groothuis, G.M.M., Hengstler, J.G., 2007. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159-234.
17. Hylan, R., Osborne, T., Payne, A., Kemshall, S., Logan, R., Ezzeddine, K., Jones, B., 2009. In vitro and in vivo glucuronidation of midazolam in humans. Br. J. Clin. Pharmacol. 67, 445-454.
18. Kedderis, G.L., Held, S.D., 1996. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 140, 124-130.
19. Kerry, N.L., Somogyi, A., Bochner, F., Mikus, G., 1994. The role of CYP2D6 in primaryand secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br. J. Clin. Pharmacol. 38, 243-248.
20. Khetani, S.R., Bhatia, S.N., 2008. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26, 120-126.
21. Kienhuis, A.S., Wortelboer, H.M., Maas, W.J., van Herwijnen, M., Kleinjans, J.C.S., van Delft, J.H.M., Stierum, R.H., 2007. A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. Toxicol. Vitro. 21, 892-990.
22. Lau, Y.Y., Sapidou, E., Cui, X., White, R.E., Cheng, K.C., 2002. Development of a novel in vitro model to predict hepatic clearance using fresh cryopreserved and sandwich-cultured hepatocytes. Drug Metab. Dispos. 30, 1446-1454.
23. Leclerc, E., Sakai, Y., Fujii, T., 2004. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Biotechnol. Prog. 20, 750-755.
24. LeCluyse, E.L., 2001. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13, 343-368.
25. Lipscomb, J.C., Poet, T.S., 2008. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 118, 82-103.
26. Maurel, P., 1996. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Deliv. Rev. 22, 105-132.
27. Novik, E., Maguire, T.J., Chao, P., Cheng, K.C., Yarmush, M.L., 2010. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 79, 1036-1044.
28. Prot, J.-M., Aninat, C., Griscom, L., Razan, F., Brochot, C., Guguen Guillouzo, C., Legallais, C., Corlu, A., Leclerc, E., 2011. Improvement of HepG2/C3a cell functions in a microfluidic biochip, Biotechnol. Bioeng., in press.
29. Richert, L., Abadie, C., Bonet, A., Heyd, B., Mantion, G., Alexandre, E., Bachellier, P., Kingston, S., Pattenden, C., Illouz, S., Dennison, A., Hoffmann, S., Coecke, S., 2010. Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - A European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. Toxicol. Vitro. 24, 335-345.
30. Sivaraman, A., Leach, J.K., Townsend, S., Iida, T., Hogan, B.J., Stolz, D.B., Fry, R., Samson, L.D., Tannenbaum, S.R., Griffith, L.G., 2005. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug. Metab. 6, 569-591.
31. Soars, M.G., McGinnity, D.F., Grime, K., Riley, R.J., 2007. The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact. 168, 2-15.
32. Strauch, K., Lutz, U., Bittner, N., Lutz, W., 2009. Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated byhumanurinary metabolite profiles. Food Chem. Toxicol. 47, 1928-1935.
33. Tilles, A., Baskaran, H., Roy, P., Yarmush, M., Toner, M., 2001. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotech. Bioeng. 73, 379-389.
34. Videau, O., Delaforge, M., Levi, M., Thévenot, E., Gal, O., Becquemont, L., Beaune, P., Bénech, H., 2010. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun. Mass Spectrom. 24, 2407-2419.
35. Vossen, M., Sevestre, M., Niederalt, C., Jang, I., Willmann, S., Edginton, A.N., 2007. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically based pharmacokinetic (WB-PBPK) models. Theor. Biol. Med. Modell. 4, 1-15.
36. Yu, H., Meyvantsson, I., Shkel, I.A., Beebe, D.J., 2005. Diffusion dependent cell behavior in microenvironments. Lab Chip. 5, 1089-1095. (Pubitemid 41452999)